Patients with only one mutated copy of the DDC gene may present delayed or milder symptoms of AADC deficiency — including behavioral abnormalities as sole manifestations — that often lead to late diagnosis and further complications, a case report shows. The study, “When dysphoria is not a primary…
News
Antisense oligonucleotides (ASOs) — short nucleic acid molecules used to modulate protein production — can be used to correct abnormal dopa decarboxylase (DDC) processing in cells from patients with aromatic L-amino acid decarboxylase (AADC) deficiency, a new study reports. The study, “Antisense oligonucleotides modulate dopa decarboxylase function in…
PTC Therapeutics plans to request approval for its GT-AADC gene therapy, developed for the treatment of aromatic L-amino acid decarboxylase (AADC) deficiency, in the United States. Supported by positive data from clinical studies, the company expects to submit a biologics license application (BLA) with the U.S. Food and Drug Administration…
Recent Posts
- The lessons from the first 7 years that helped us stop chasing a timeline
- Genetic testing may help tailor medications for rare disease patients
- Building curiosity can nurture a voice before the words arrive
- Illumina teams with FSU lab to expand genome testing for rare diseases
- Why awareness about rare disease must begin in school